Literature DB >> 9834116

Identification of a truncated form of the CC chemokine CK beta-8 demonstrating greatly enhanced biological activity.

C H Macphee1, E R Appelbaum, K Johanson, K E Moores, C S Imburgia, J Fornwald, T Berkhout, M Brawner, P H Groot, K O'Donnell, D O'Shannessy, G Scott, J R White.   

Abstract

A new CC chemokine, designated CKbeta-8 or myeloid progenitor inhibitor factor-1, was recently identified in a large scale sequencing effort and was cloned from a human aortic endothelial library. CKbeta-8 cDNA encodes a signal sequence of 21 amino acids, followed by a 99-amino acid predicted mature form. CKbeta-8 was expressed and purified from a baculovirus insect cell expression system, which resulted in the identification of different N-terminal variants of the secreted chemokine. The three major forms (containing amino acids 1-99, 24-99, and 25-99 of the secreted chemokine) showed a large variation in potency. CKbeta-8 activated both monocytes and eosinophils to mobilize intracellular calcium; however, the shortest form of CKbeta-8 (25-99) was >2 orders of magnitude more potent than the longest form. Cross-desensitization experiments in both monocytes and eosinophils suggested that the CCR1 receptor was probably the predominant receptor that mediates this chemokine's physiologic response. However, incomplete desensitization was encountered in both cell systems, suggesting involvement of an additional receptor(s). Interestingly, the short form of CKbeta-8 was the most potent chemotactic chemokine that we have ever evaluated in the monocyte system (EC50 = 54 pM). However, in contrast to its action on monocytes, CKbeta-8 was a very poor chemotactic factor for eosinophils.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834116

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration.

Authors:  David Vergote; Georgina S Butler; Martine Ooms; Jennifer H Cox; Claudia Silva; Morley D Hollenberg; Jack H Jhamandas; Christopher M Overall; Christopher Power
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

2.  Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.

Authors:  Chuan-Chu Chou; Jay S Fine; Catherine Pugliese-Sivo; Waldemar Gonsiorek; Liza Davies; Gregory Deno; Mary Petro; Martin Schwarz; Paul J Zavodny; R William Hipkin
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

3.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

4.  Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16.

Authors:  Amanda E Starr; Antoine Dufour; Josefine Maier; Christopher M Overall
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

5.  Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis.

Authors:  B A Zabel; W W Agace; J J Campbell; H M Heath; D Parent; A I Roberts; E C Ebert; N Kassam; S Qin; M Zovko; G J LaRosa; L L Yang; D Soler; E C Butcher; P D Ponath; C M Parker; D P Andrew
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

Review 6.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.

Authors:  Jan Korbecki; Klaudyna Kojder; Donata Simińska; Romuald Bohatyrewicz; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.